Evidence map›Paper›PMID 40279091›Full record

ReviewCurrent treatment options in oncology2025

Locoregional Non-Surgical Treatments for Unresectable or Oligometastatic Sarcomas: A Literature Review.

Annarita Peddio, Antonio Pizzolorusso, Ottavia Clemente, Lucia Cannella, Flavia Balzamo, Giuseppina Della Vittoria Scarpati, Federica Papa, Fernanda Picozzi, Carmela Garosi, Debora De Bartolo and 2 more

Abstract readReview
In one paragraph

Review in Current treatment options in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Annarita PeddioDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Antonio PizzolorussoSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S. Fondazione "G.Pascale", Naples, Italy. a.pizzolorusso@istitutotumori.na.it.
Ottavia ClementeSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S. Fondazione "G.Pascale", Naples, Italy.
Lucia CannellaSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S. Fondazione "G.Pascale", Naples, Italy.
Flavia BalzamoSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S. Fondazione "G.Pascale", Naples, Italy.
Giuseppina Della Vittoria ScarpatiSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S. Fondazione "G.Pascale", Naples, Italy.
Federica PapaSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S. Fondazione "G.Pascale", Naples, Italy.
Fernanda PicozziSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S. Fondazione "G.Pascale", Naples, Italy.
Carmela GarosiSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S. Fondazione "G.Pascale", Naples, Italy.
Debora De BartoloPathology Unit, Istituto Nazionale Tumori I.R.C.C.S, Fondazione "G. Pascale", Naples, Italy.
Francesco FioreInterventional Radiology Unit, Istituto Nazionale Tumori I.R.C.C.S, Fondazione "G. Pascale", Naples, Italy.
Salvatore TafutoSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori I.R.C.C.S. Fondazione "G.Pascale", Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementSarcomas are rare neoplasms, whose complex management is a consequence of their heterogeneity. Due to their variegate histology and characteristics, prospective trials are challenging to design. Thus, diagnostic and therapeutic guidelines are often based on limited evidence available, and only few and dated systemic treatment regimens are included in our current practice. For all these reasons, we believe that implementing therapeutic options, including local approach, is mandatory to guarantee the best management possible to patients. We explored evidence about locoregional treatments, assuming they could represent a fundamental part of an integrated oncological approach. The goal is to maximize local control of oligometastatic or oligoprogressive diseases, saving systemic treatment options for later stages, as well as to avoid demolitive surgery in patients affected by locally advanced sarcomas. Although several retrospective and prospective series have been conducted, evidence available is still poor in our opinion. Research should focus on evaluating predictive factors and individualized follow up strategies to identify ideal patients' features and more sensitive histological subtypes.

Indexed as

SarcomaCombined Modality TherapyDisease ManagementHumansNeoplasm MetastasisNeoplasm StagingTreatment OutcomeLocoregional approachLocoregional treatmentOligometastatic diseaseSarcoma

Identifiers

PMID40279091
PMCPMC12055889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.